Haohai biological invalidates restricted shares, acquires equity in Ruiji biotech

Shanghai Haohai Biological Technology has announced the invalidation of 225,002 granted but unvested restricted shares from its 2021 A-share restricted stock incentive plan. This decision, approved by the sixth board of directors on December 12, 2025, follows the expiry of the second vesting period for these restricted shares, effectively concluding the incentive plan.

Concurrently, the company is set to acquire 8,466,112 shares, representing 19.8000% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for a total consideration of yuan 38,351,487.36. This acquisition aims to enhance Haohai Biological's product portfolio and expand into the high-value medical device sector, specifically in biological amnion products for ophthalmic and orthopedic fields.

This equity acquisition is structured in three phases, with the first phase expected to close by December 31, 2025, and the final phase by July 31, 2026. The company anticipates no significant impact on its financial stability, operational independence, or core team.